Last reviewed · How we verify

NCT05002881

A Study to Explore the Effect of Moringa Oleifera (E-HS-01) on Flow Mediated Dilatation and Hemodynamics

Status unknown NA Last updated 22 February 2022
What this trial tests

NA trial testing Moringa oleifera (E-HS-01) in Endothelial Function in 60 participants. Status unknown.

Timeline
16 August 2021
Primary endpoint
31 March 2022
31 March 2022

Quick facts

Lead sponsorVedic Lifesciences Pvt. Ltd.
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposeother
Enrollment60
Start date16 August 2021
Primary completion31 March 2022
Estimated completion31 March 2022
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Vedic Lifesciences Pvt. Ltd. — full company profile →

Who can join

Adults 20 to 35, male only, with Endothelial Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study is designed to evaluate the modulatory effect of IP on the vascular endothelial function. To assess its vasodilatation potential, change in flow mediated dilation (FMD) and blood flow velocity (BFV) will be assessed in healthy adult male population.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The "Colors" of Moringa: Biotechnological Approaches.
    Villegas-Vazquez EY, Padilla-Mendoza JR, Carrillo-Pérez MS, Gómez-Cansino R, et al · · 2025 · PMID 40805688 · DOI 10.3390/plants14152338

Verify or expand the search:

Other recruiting trials for Endothelial Function

Currently open trials in the same condition.

Other Vedic Lifesciences Pvt. Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05002881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing